BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Bladder and urothelial cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for urothelial carcinoma: 145 (97 sponsors; 16 newly posted in the last 180 days, 8 stopped in the last 180 days; 9 new-entrant sponsors). Momentum score 11, rank 62 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 47, Phase 2 56, Phase 3 26, Phase 4 1, N/A 14.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Mabwell (Shanghai) Bioscience Co., Ltd.5P2 3, P3 201
UroGen Pharma Ltd. URGN3P3 2, NA 101
Merck Sharp & Dohme LLC MRK6P2 5, P3 101
Sichuan Baili Pharmaceutical Co., Ltd.6P3 1, P2 3, P1 212
Eli Lilly and Company LLY5P2 1, P3 1, P1 312
Astellas Pharma Global Development, Inc.3P4 1, P3 1, P2 101
BeiGene3P1 1, P2 1, P3 100
Daiichi Sankyo3P2 2, P3 110
Seagen, a wholly owned subsidiary of Pfizer3P2 2, P3 102
AstraZeneca AZN2P2 1, P3 110
CSPC Megalith Biopharmaceutical Co.,Ltd.2P3 1, P2 100
EMD Serono Research & Development Institute, Inc.2P3 1, P2 101
Janssen Research & Development, LLC2P2 1, P3 101
Shanghai Hengrui Pharmaceutical Co., Ltd.2P3 1, P2 100
SystImmune Inc.2P1 1, P3 110
CG Oncology, Inc. CGON1P3 100
Protara Therapeutics TARA1P3 100
Relmada Therapeutics, Inc. RLMD1P3 100
RemeGen Co., Ltd.1P3 101
Summit Therapeutics SMMT new entrant1P3 110
Suzhou Suncadia Biopharmaceuticals Co., Ltd.1P3 100
Taiho Oncology, Inc.1P3 101
Vasgene Therapeutics, Inc1P3 100
Verity Pharmaceuticals Inc.1P3 100
ImmunityBio, Inc. IBRX3P2 2, P1 100

New-entrant sponsors: Summit Therapeutics.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Theralase® Technologies Inc. TLTFFNCT03945162 Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") PatientsNon-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCGrecruiting90
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05965856 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid TumorsUrothelial Carcinoma; Solid Tumorrecruiting52
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06405425 A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial CarcinomaUrothelial Carcinomarecruiting52
2026-12-11 est.P2Seagen, a wholly owned subsidiary of PfizerNCT04879329 A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2Urothelial Carcinomarecruiting372
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-30 est.P3Janssen Research & Development, LLCNCT04658862 A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderUrinary Bladder Neoplasmsactive not recruiting518
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P1/P2BicycleTx LimitedNCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionAdvanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Canceractive not recruiting288
2026-12-31 est.P3Pfizer PFENCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingAdvanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumorsactive not recruiting77
2026-12-31 est.P3RemeGen Co., Ltd.NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaUrothelial Carcinoma; HER2-expressingrecruiting452
2026-12-31 est.P2Hoffmann-La RocheNCT05645692 A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced MetUrothelial Canceractive not recruiting204
2026-12-31 est.P1/P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06079112 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial CancerAdvanced Urothelial Carcinomarecruiting100
2026-12-31 est.P2Jazz Pharmaceuticals JAZZNCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsBreast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endomerecruiting200
2027-01 est.P1/P2BicycleTx LimitedNCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesUrinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negativeactive not recruiting329
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-01-29 est.P3Seagen, a wholly owned subsidiary of PfizerNCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Urothelial Carcinomaactive not recruiting412
2027-01-31 est.P3Merck Sharp & Dohme LLC MRKNCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99Urinary Bladder Neoplasmsactive not recruiting520

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2ImmunityBio, Inc. IBRXNCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder CancerNon-muscle Invasive Bladder Cancer (NMIBC)not yet recruiting20
2026-11 est.P3CG Oncology, Inc. CGONNCT06111235 A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTNon Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer; Urothelial Carcinomaactive not recruiting367
2026-11 est.P1/P2Tyra Biosciences, Inc TYRANCT05544552 Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsLocally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor; Urothelial Carcactive not recruiting310
2026-09-30P1/P2Merck Sharp & Dohme LLC MRKNCT06637423 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)Non-Muscle Invasive Bladder Cancercompleted35
2026-09-30 est.P1/P2ImmunityBio, Inc. IBRXNCT02138734 A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerNon-muscle Invasive Bladder Canceractive not recruiting369
2026-09 est.P3Mabwell (Shanghai) Bioscience Co., Ltd.NCT06196736 A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial CancerAdvanced Urothelial Carcinomarecruiting432
2026-07 est.P3Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06738251 A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial CarcinomaAdvanced Urothelial Carcinomarecruiting402
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-06-01P3AstraZeneca AZNNCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Canceractive not recruiting1246
2026-06 est.P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06823427 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial CarcinomaUrothelial Carcinoma; Urothelial Carcinoma Bladder; Urothelial Carcinoma Recurrent; Urothelial Carcirecruiting60
2026-06 est.P2Vaneltix Pharma, Inc.NCT06394830 Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)Interstitial Cystitis; Bladder Pain Syndromerecruiting50
2026-06 est.P2Vaneltix Pharma, Inc.NCT05737121 Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPSInterstitial Cystitis; Bladder Pain Syndromerecruiting120

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "urothelial carcinoma"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.